Datapoint: FDA Approves Coherus Lucentis Copy

The FDA last week approved Coherus BioSciences, Inc.’s Lucentis biosimilar, Cimerli, across all five of its indications. The anti-VEGF therapy will be interchangeable with Lucentis, a blockbuster for manufacturer Roche, and hold interchangeability exclusivity for 12 months. The first Lucentis biosimilar, Byooviz, was approved in September 2021, but for just three of Lucentis’s indications, including wet age-related macular degeneration (AMD). For the treatment of AMD, Lucentis holds covered or better status for 86% of all insured lives under the medical benefit, to Byooviz’s 68%.

SOURCE: MMIT Analytics, as of 8/8/22

0

0

0 Comments

0

0

• Datapoint